ENTRY       D00142                      Drug
NAME        Methotrexate (JP17/USP/INN);
            Otrexup (TN)
PRODUCT     OTREXUP (Antares Pharma) 9ab8ce16-f7de-41d4-a4c8-1c742621b6d5
            XATMEP (Silvergate Pharmaceuticals) aec9984e-34c5-481b-b6bf-9bb5caf1daf8
  GENERIC   METHOTREXATE (Accord Healthcare) dd035a9f-cd40-4314-b9d8-2294b8a924e2
            METHOTREXATE (Cadila Healthcare Limited) 59ea7b32-2b6d-4197-92c3-015936f04ebe
            METHOTREXATE (Mylan Institutional) 8df0780e-0fbd-4ab8-80b0-7a5eaa08ec0a
            METHOTREXATE (Mylan Institutional LLC) 57b2face-9edd-4aea-bbc4-938249aa2267
            METHOTREXATE (Mylan Institutional LLC) f13eeab7-f376-4912-aef2-450ea027de6d
            METHOTREXATE (Mylan Pharmaceuticals) 70c09984-2b36-424f-8b27-3fd0cd4e833d
            METHOTREXATE (Pfizer Laboratories Div Pfizer) 4767fe9f-aa42-46cd-8101-9df7101f55e1
            METHOTREXATE (Pfizer Laboratories Div Pfizer) 5c960719-19a3-442d-a24b-189b4760ab69
            METHOTREXATE (Physicians Total Care) 47bb478d-0e3e-423a-9737-1231152add1d
            METHOTREXATE (West-Ward Pharmaceuticals Corp) b080eb92-fc72-4ce6-a7ab-3f9ce2415526
            METHOTREXATE (Zydus Pharmaceuticals (USA)) 948e0bab-6524-4b87-9853-1799d4415558
FORMULA     C20H22N8O5
EXACT_MASS  454.1713
MOL_WEIGHT  454.4393
CLASS       Antineoplastic
             DG01930  Dihydrofolate reductase inhibitor, antineoplastic
             DG01978  Folic acid analogue
              DG01930  Dihydrofolate reductase inhibitor, antineoplastic
            Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drugs (DMARDs)
            Transporter substrate
             DG01913  BCRP substrate
            Unclassified
             DG02018  Antimetabolite
              DG01978  Folic acid analogue
               DG01930  Dihydrofolate reductase inhibitor, antineoplastic
REMARK      Same as: C01937
            Therapeutic category: 3999 4222
            ATC code: L01BA01 L04AX03
            Chemical group: DG00681
ACTIVITY    Antineoplastic, Antimetabolite
TARGET      DHFR [HSA:1719 200895] [KO:K00287]
  PATHWAY   hsa00670(1719+200895)  One carbon pool by folate
            hsa00790(1719+200895)  Folate biosynthesis
METABOLISM  Transporter: SLC22A6 [HSA:9356], SLC22A8 [HSA:9376], SLCO1A2 [HSA:6579], ABCG2 [HSA:9429], ABCC2 [HSA:1244], ABCC3 [HSA:8714], ABCC4 [HSA:10257]
INTERACTION  
STR_MAP     map07041  Antineoplastics - antimetabolic agents
            map07046  Immunosuppressive agents
            map07050  Antirheumatics - DMARDs and biological agents
OTHER_MAP   map01523  Antifolate resistance
            map04976  Bile secretion
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01B ANTIMETABOLITES
                L01BA Folic acid analogues
                 L01BA01 Methotrexate
                  D00142  Methotrexate (JP17/USP/INN)
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AX Other immunosuppressants
                 L04AX03 Methotrexate
                  D00142  Methotrexate (JP17/USP/INN)
            USP drug classification [BR:br08302]
             Immunological Agents
              Immune Suppressants
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D00142  Methotrexate (JP17/USP/INN)
             4  Agents affecting cellular function
              42  Antineoplastics
               422  Antimetabolites
                4222  Methotrexates
                 D00142  Methotrexate (JP17/USP/INN)
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Oxidoreductases
               dihydrofolate reductase
                Methotrexate
                 D00142  Methotrexate (JP17/USP/INN)
            Cytochrome P450 interactions [BR:br08309]
             Transporter substrates
              ABCC2
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              ABCC3
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              ABCC4
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              ABCG2
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              OAT1
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              OAT3
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
              SLCO1A2
               Methotrexate
                D00142  Methotrexate (JP17/USP/INN)
            Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
             Chemicals
              D00142  Methotrexate
              D00142  Methotrexate capsules
            Antineoplastics [br08340.html]
             D00142
            Antirheumatic and antigout drugs [br08366.html]
             Antirheumatic drugs
              D00142
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00142
DBLINKS     CAS: 59-05-2
            PubChem: 7847210
            ChEBI: 44185
            ChEMBL: CHEMBL34259
            DrugBank: DB00563
            PDB-CCD: MT1 MTX
            LigandBox: D00142
            NIKKAJI: J2.334E
ATOM        33
            1   C8y C     8.3300  -28.0700
            2   N5x N     8.3300  -29.4700
            3   C8y C     9.5424  -30.1700
            4   C8y C    10.7549  -29.4700
            5   C8y C    10.7549  -28.0700
            6   N5x N     9.5424  -27.3700
            7   N5x N    11.9673  -30.1700
            8   C8y C    13.1797  -29.4700
            9   C8x C    13.1797  -28.0700
            10  N5x N    11.9673  -27.3700
            11  N1a N     7.1176  -27.3700
            12  N1a N     9.5424  -31.5698
            13  C1b C    14.3773  -30.1615
            14  N1c N    15.5656  -29.4755
            15  C8y C    16.7564  -30.1631
            16  C1a C    15.5657  -28.0702
            17  C8x C    16.7564  -31.5698
            18  C8x C    17.9688  -32.2698
            19  C8y C    19.1812  -31.5698
            20  C8x C    19.1812  -30.1632
            21  C8x C    17.9688  -29.4631
            22  C5a C    20.3928  -32.2693
            23  N1b N    21.5877  -31.5793
            24  O5a O    20.3929  -33.6698
            25  C1c C    22.7754  -32.2649
            26  C1b C    23.9665  -31.5770
            27  C1b C    25.1560  -32.2638
            28  C6a C    26.3461  -31.5765
            29  O6a O    27.5362  -32.2635
            30  C6a C    22.7755  -33.6698
            31  O6a O    23.9689  -34.3588
            32  O6a O    21.5440  -34.3811
            33  O6a O    26.3462  -30.1702
BOND        35
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    5  10 1
            12    1  11 1
            13    3  12 1
            14    8  13 1
            15   13  14 1
            16   14  15 1
            17   14  16 1
            18   15  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   15  21 1
            24   19  22 1
            25   22  23 1
            26   22  24 2
            27   23  25 1
            28   25  26 1
            29   26  27 1
            30   27  28 1
            31   28  29 1
            32   25  30 1 #Up
            33   30  31 1
            34   30  32 2
            35   28  33 2
///
